Education
About Us
Working with TipRanks
Follow Us
Stevanato Group (STVN)
NYSE:STVN
Earnings Data
Report Date
May 07, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.13Last Year’s EPS
0.12Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong execution in high-value biopharmaceutical products, with meaningful revenue and margin expansion driven by BDS, high-value solutions and GLP-1 demand; operational investments (Latina, Fishers) and positive free cash flow support the growth strategy. Key challenges include a materially weaker Engineering segment (notably lower Q4 revenue and slower order conversion), FX/tariff headwinds, heavy near-term CapEx and some capacity ramp timing risk. On balance, the positive drivers (robust top-line growth, high-value mix, margin expansion, positive FCF, and constructive 2026 guidance) significantly outweigh the identified negatives.Company Guidance
Full-Year Revenue Growth
Total company revenue for fiscal 2025 increased 9% at constant currency and 7% on a reported basis versus 2024, delivering the company guidance-backed growth and positive momentum heading into 2026.
Biopharmaceutical & Diagnostic Solutions (BDS) Outperformance
BDS delivered double-digit full-year growth and finished the fourth quarter with revenue up 13% at constant currency (10% reported) to EUR 307.1 million, offsetting Engineering weakness and driving consolidated results.
High-Value Solutions — Strong Growth and Mix Impact
Revenue from high-value solutions rose 29% for fiscal 2025 and grew 31% in Q4 to EUR 171 million, representing ~46% of full-year company revenue and ~49% of Q4 company revenue—materially contributing to margin expansion.
GLP-1 Tailwind
Revenue from GLP-1 related products accounted for ~19%–20% of total company revenue in 2025 and grew more than 50% year-over-year; management expects GLP-1s to remain a meaningful tailwind, projecting mid-teens GLP-1 growth in 2026.
Margin Expansion
Full-year gross profit margin expanded ~160 basis points versus 2024; Q4 gross profit margin increased 120 basis points to 30.9%, supported by favorable mix toward high-value products and improved utilization at new facilities.
Profitability and Adjusted Metrics (Q4)
Q4 net profit was EUR 47.6 million (diluted EPS EUR 0.17), adjusted net profit EUR 49.8 million (adjusted diluted EPS EUR 0.18). Adjusted EBITDA increased 7% to EUR 97.7 million with adjusted EBITDA margin up 70 basis points to 28.2%.
Positive Free Cash Flow and Strong Operational Cash Generation
For fiscal 2025, cash from operations was EUR 286.1 million and the company generated positive free cash flow of EUR 18.4 million after capital expenditures of EUR 294.9 million (≈89% deployed to growth projects).
2026 Financial Guidance Reflects Continued Growth
Management provided 2026 guidance: revenue EUR 1.260–1.290 billion (constant currency EUR 1.278–1.308 billion), adjusted EBITDA EUR 331.8–346.9 million, adjusted diluted EPS EUR 0.59–0.63, and expected high-value solutions of 47%–48% of revenue.
Strategic Capacity Investments and Global Footprint
Significant investments and ramp activities in Latina (syringe capacity, upcoming EZ-fill cartridge capacity) and Fishers (line installations, customer validations, contract manufacturing build-out) position the company to scale high-value production and serve U.S. onshoring demand.
STVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
STVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 04, 2026 | $14.73 | $17.50 | +18.81% |
Nov 06, 2025 | $25.00 | $24.41 | -2.36% |
Aug 05, 2025 | $25.58 | $23.09 | -9.73% |
May 08, 2025 | $21.74 | $22.42 | +3.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Stevanato Group (STVN) report earnings?
Stevanato Group (STVN) is schdueled to report earning on May 07, 2026, Before Open (Confirmed).
What is Stevanato Group (STVN) earnings time?
Stevanato Group (STVN) earnings time is at May 07, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is STVN EPS forecast?
STVN EPS forecast for the fiscal quarter 2026 (Q1) is 0.13.